![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/12/2928777/0/en/BioStem-Technologies-Reports-Record-Second-Quarter-2024-Revenue-of-74-5-Million.html
https://www.globenewswire.com/news-release/2024/08/05/2924223/0/en/BioStem-Technologies-to-Report-Second-Quarter-2024-Financial-Results-on-Monday-August-12-2024.html
https://www.biospace.com/article/releases/biostem-receives-institutional-review-board-irb-approval-to-advance-a-clinical-study-evaluating-amniowrap2-in-diabetic-foot-ulcers/
https://www.globenewswire.com/news-release/2024/07/10/2911013/0/en/BioStem-Receives-Institutional-Review-Board-IRB-Approval-to-Advance-a-Clinical-Study-Evaluating-AmnioWrap2-in-Diabetic-Foot-Ulcers.html
https://www.globenewswire.com/news-release/2024/06/26/2904491/0/en/BioStem-Technologies-Reports-Breakthrough-Results-with-AmnioWrap2-in-Retrospective-Wound-Care-Study.html
https://www.globenewswire.com/news-release/2024/05/29/2890071/0/en/BioStem-Technologies-to-Sponsor-MRO-Better-Half-Dash.html
https://www.globenewswire.com/news-release/2024/05/14/2881839/0/en/BioStem-Technologies-Reports-Record-First-Quarter-Revenue-of-41-9-Million.html
https://www.globenewswire.com/news-release/2024/05/07/2876646/0/en/BioStem-Technologies-to-Report-First-Quarter-2024-Financial-Results-on-Tuesday-May-14-2024.html
https://www.globenewswire.com/news-release/2024/05/06/2875792/0/en/BioStem-Technologies-Granted-Prioritized-Examination-for-Wound-Healing-Patent.html
https://www.globenewswire.com/news-release/2024/04/30/2872257/0/en/BioStem-Technologies-Retains-Clinical-Research-Industry-Veteran-Nick-McCoy-to-Lead-DFU-and-VLU-trials-for-BioREtain-Allografts.html